We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

4,200
Open access books available

116,000
International authors and editors

125M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Chapter

Neuropathology of Traumatic Brain Injury and Its Role in the Development of Alzheimer’s Disease
Sonia Villapol

Abstract

The devastating deficiencies that result from brain injury stem from multiple overlapping mechanisms, exacerbated by the fact that there are no effective treatments. Traumatic brain injury (TBI) is recognized as the most influential environmental risk factor for neurodegenerative disease later in life, including dementia of Alzheimer’s disease (AD)-type. However, exactly how TBI triggers and strengthens the neurodegenerative cascade of events in AD remains controversial. Amyloid deposits and fibril precursor protein are extracellular in systemic amyloid A (AA) amyloidosis. In this chapter, I will discuss the neuropathology following TBI connected to AD. Additionally, I critically review recent animal and human studies regarding how brain trauma affects the potential risks factors for AD progression. Furthermore, it will be shown investigate the principal pathological features of dementia or AD, specifically focusing on axonal damage and consequent cleavage of the amyloid precursor protein (APP), amyloid β plaque formation, or phosphorylation and aggregation of tau, neurofibrillary tangles formation, and TDP-43 accumulation. In summary, despite recent progress more studies are required to (1) further understanding of the basic mechanisms and pathophysiology of TBI, (2) elucidate the precise association between TBI and neurodegenerative disease, and (3) to identify treatments and therapies that can mitigate long-term consequences.

Keywords: tau, TDP-43, neurodegenerative, dementia, amyloid beta, plaques, amyloid beta deposition

1. Introduction

Traumatic brain injury (TBI) affects millions of individuals worldwide, with 1.7 million new cases in the US each year [1]. Although many patients survive the initial lesion, TBI initiates a wide variety of pathologies such as neurological deficits, short and long-term brain damage, neuroinflammation, cognitive and emotional impairments, all of which depend on the severity of the injury and other various factors [2, 3]. Brain injuries are most frequently caused by motor vehicle crashes, sports injuries, or simple falls; males are about twice as likely as females to experience a brain trauma [4]. At least 5.3 million Americans, or approximately 2% of the total US population, currently are burdened with disabilities resulting from TBI [5].
Functional deficits caused by TBI result from an initial impact and secondary damage that continue to develop over time and provide a therapeutic window for treatment to prevent or ameliorate many of the damaging consequences of injury [6]. While single compounds have been reported to be effective for short periods in standardized rodent models of TBI, therapeutic tools currently available to clinicians to treat patients with TBI are minimal.

The neuroinflammatory cascade following TBI contributes to neurodegeneration and death through the cumulative action of multiple damaging processes [7]. TBI is one of the most consistent candidates for initiating the molecular cascades that result in neurodegenerative diseases, such as Parkinson’s disease (PD) or amyotrophic lateral sclerosis (ALS) [8–11]. Notably, there exists a strong epidemiological relationship between the occurrence of TBI and the development of Alzheimer’s disease (AD) later in life [12–15]. The link between TBI and AD is strengthened through the identification of acute and chronic AD-like pathologies in the brain in both TBI survivors and animal models of brain injury.

AD is a progressive neurodegenerative disease, which can only be fully diagnosed at autopsy. It is characterized, histologically, by the presence of amyloid plaques and intracellular neurofibrillary tangles (NFT) in the brain [16]. The amyloid plaques consist of aggregated proteinaceous material, a significant component of amyloid β (Aβ). The tangles are composed of paired helical filaments (PHF) of the microtubule-associated phosphoprotein tau [16, 17]. In this chapter, I will describe the main pathological similarities, and differences, between TBI and AD. Although the evidence suggests that TBI is a risk factor for dementia, very little is known about what type, frequency, or severity of trauma is necessary to induce dementia [18].

A chronic disease process is initiated after TBI, known as the secondary injury cascade, and as part of this process, neuroinflammation, neuronal loss, or the production, aggregation and clearance of Aβ peptides occurs [19]. Several of these pathophysiological features have been characterized in patients with AD with similar neuropathology. Furthermore, epidemiological studies have shown how repetitive injury, or a single mild, moderate, or severe TBI, can cause a wide range of proteinopathies [20], and likely contribute to the later onset of debilitating neurodegenerative diseases. Indeed, the human pathology of survival from TBI is best described as a “polypathology”, featuring Aβ, tau, and TDP-43 pathologies, together with white matter degradation, neuronal loss, and neuroinflammation [21]. There exist many pathological features common to both acute brain injury and AD, including Aβ deposition, tau phosphorylation, neurite degeneration, synapse loss and microgliosis [22]. Besides, the susceptibility of the patient may be predetermined by multiple factors such as age, sex and the interplay of several genetic factors [23–25].

The purpose of this chapter is to discuss the neuropathology and genetic risk factors associated with TBI that may collectively shed some light on the risk of developing dementia or AD following head trauma, as well as possible treatments in animal models and human studies.

2. Traumatic brain injury, neuroinflammation, and its link with Alzheimer’s disease

Postmortem studies in human populations have shown microglia activation many years after TBI. Innate activation of microglia generally leads to amyloidogenic APP processing and the generation of Aβ plaques. Aβ plaques formed during the initial weeks after injury may regress with time. In this case, a continuously
renewed store of Aβ in degenerating axons can be kept in check through degeneration by endogenous mediators or anti-inflammatory phagocytic microglia, or macrophages. A deficiency in microglia clearance of Aβ could possibly account for this balance shift, especially since aging microglia are known to have a reduction in phagocytic capacity and this is also observed in AD, the most common age-related dementia [13].

Compelling epidemiological evidence indicates that moderate and severe TBI is associated with increased risk of development of progressive disorders of cognitive impairment leading to dementia or AD [15, 26–28]. Therefore, TBI is considered as a strong epigenetic risk factor for AD [29, 30]. Aβ plaques, a hallmark of AD, are found in 30% of patients who do not survive TBI [13]. A history of TBI is a strong risk factor for AD, although there remains a lack of clear consensus around this topic since a few epidemiological studies have not uncovered such an association [31]. However, there exists strong evidence linking TBI to AD-related pathologies [32, 33]. Moderate and severe head injury increased the risk of AD for 2.3 and 4.5 times, respectively [30]. Although there is clinical evidence linking TBI and AD pathologies, there is an important lack of knowledge specific to the mechanisms driving this link.

In follow up studies, an increased incidence of head trauma in those with AD has been found only in males, not in females, and the risk of developing AD after TBI focused on injury severity [4, 25]. In studies where these criteria are more broadly defined, we can analyze the relative risk from head trauma of differing severity; it has been suggested [8] that a prior history of TBI accelerates the onset of AD and that the higher the incidence of severe the injury, the higher the risk of developing AD. Roberts et al. provided one of the first studies to closely examine Aβ deposition after TBI [34] (Table 1). Data from subsequent studies have suggested that even a single moderate to severe TBI event is a significant risk factor for the later onset of dementia or AD [35, 36].

However, it remains unknown whether patients with prior brain damage instead develop a distinct clinical phenotype of dementia, different from that of the typical AD. Examination of human brain samples confirmed that TBI

<table>
<thead>
<tr>
<th>Patients (N)</th>
<th>Category of TBI</th>
<th>Pathology associated, postmortem tissue</th>
<th>Time after injury</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>Severe TBI</td>
<td>38% Aβ deposits, diffuse plaques</td>
<td>18 days of TBI</td>
<td>[34]</td>
</tr>
<tr>
<td>152</td>
<td>Severe TBI</td>
<td>30% Aβ diffuse deposits</td>
<td>Several times</td>
<td>[96]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20% (under 40) Aβ plaques</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>70% (60–80 age) Aβ plaques (50% controls)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>TBI</td>
<td>Aβ42 peptide, 30% Aβ diffuse deposits</td>
<td>Several times</td>
<td>[97]</td>
</tr>
<tr>
<td>18</td>
<td>Severe TBI</td>
<td>33% Aβ deposits, Aβ42 peptide, diffuse plaques</td>
<td>2–19 h</td>
<td>[36]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>80% neuronal/glial intracellular Aβ peptides tau (PHF-1) axons</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>TBI</td>
<td>Aβ42 peptide, axonal damage, APP deposits, neurofilament, β-secretase, g-secretase Tau-positive astrocytes</td>
<td>4 h–5 days</td>
<td>[22]</td>
</tr>
<tr>
<td>11</td>
<td>TBI</td>
<td>Tau-positive oligodendrocytes</td>
<td>2 h</td>
<td>[107]</td>
</tr>
</tbody>
</table>

Table 1. *Patients with TBI and associated AD pathology.*
## Amyloid Diseases

<table>
<thead>
<tr>
<th>Animals</th>
<th>Animal injury model</th>
<th>Pathology associated to AD</th>
<th>Time post-injury</th>
<th>Brain regions</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse (Tg2576)</td>
<td>Controlled cortical impact</td>
<td>Increase Aβ40 and Aβ42 levels</td>
<td>9–16 weeks</td>
<td>Cortex</td>
<td>[92]</td>
</tr>
<tr>
<td>Mouse (wild-type)</td>
<td>Controlled cortical impact</td>
<td>Increase Aβ40 oligomers and Aβ42 levels, Increase pTau</td>
<td>3 days</td>
<td>Hippocampus</td>
<td>[37]</td>
</tr>
<tr>
<td>Mouse (3xTg-AD)</td>
<td>Repetitive mild TBI</td>
<td>Increase pTau</td>
<td>1 day</td>
<td>Fimbria</td>
<td>[93]</td>
</tr>
<tr>
<td>Mouse (3xTg-AD)</td>
<td>Controlled cortical impact</td>
<td>Increase Aβ40 levels, Increase totalTau and pTau</td>
<td>1–24 h and 7 days</td>
<td>Cortex</td>
<td>[76, 108]</td>
</tr>
<tr>
<td>Mouse (h-Tau)</td>
<td>Repetitive mTBI</td>
<td>Increase pTau</td>
<td>21 d</td>
<td>Cortex</td>
<td>[77]</td>
</tr>
<tr>
<td>Mouse (APP-WAC)</td>
<td>Controlled cortical impact</td>
<td>Decrease Aβ40 levels, but not Aβ42</td>
<td>1 week</td>
<td>Cortex</td>
<td>[109]</td>
</tr>
<tr>
<td>Mouse (APPNLh/NLh)</td>
<td>Controlled cortical impact</td>
<td>Decrease of caspase-3 by administration of a pan-caspase inhibitor, Reduction of caspase-cleaved APP, Aβ40, Improved histological outcome</td>
<td>24 h and 14 days</td>
<td>Cortex</td>
<td>[43]</td>
</tr>
<tr>
<td>Mouse (BACE knock-out)</td>
<td>Controlled cortical impact</td>
<td>Administration of simvastatin resulted in decreased Aβ levels, Decreased hippocampal tissue loss, Behavioural outcome improved</td>
<td>3 h</td>
<td>Hippocampus</td>
<td>[110]</td>
</tr>
<tr>
<td>Mouse (PDAPP)</td>
<td>Controlled cortical impact</td>
<td>Increase Aβ40, Improved histological, behavioural outcomes following injury, Administration of a γ-secretase inhibitor (DAPT) in non-transgenic mice, Improved outcomes</td>
<td>1–7 days</td>
<td>Cortex and hippocampus</td>
<td>[19]</td>
</tr>
<tr>
<td></td>
<td>Controlled cortical impact</td>
<td>Increase Aβ40</td>
<td>23 days</td>
<td>Hippocampus</td>
<td>[111]</td>
</tr>
<tr>
<td></td>
<td>Controlled cortical impact</td>
<td>Increase Aβ40 and Aβ42 levels, Increase neuronal death and memory impairment, No Aβ plaques</td>
<td>2 h–2 months</td>
<td>Cortex and hippocampus</td>
<td>[90]</td>
</tr>
<tr>
<td></td>
<td>Controlled cortical impact</td>
<td>Decrease in Aβ plaques</td>
<td>2, 5 and 8 months</td>
<td>Cortex and hippocampus</td>
<td>[91]</td>
</tr>
<tr>
<td></td>
<td>Controlled cortical impact</td>
<td>Decrease in Aβ plaques</td>
<td>16 weeks</td>
<td>Hippocampus</td>
<td>[103]</td>
</tr>
</tbody>
</table>
processes were the principal driver of accumulation of Aβ peptides in swollen axons shortly after TBI, which persisted for years following the initial trauma [13]. In addition to such clinical studies, there exist multiple types of brain injuries in different animal models of AD. These animal models have been used to examine the formation, aggregation, and accumulation of Aβ after injury; almost all of these are demonstrated an elevation in Aβ levels after TBI (Table 2).

<table>
<thead>
<tr>
<th>Animals</th>
<th>Animal injury model</th>
<th>Pathology associated to AD</th>
<th>Time post-injury</th>
<th>Brain regions</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse (PDAPP) and Tg2576</td>
<td>Controlled cortical impact</td>
<td>Increase Aβ baseline in transgenic and decrease Aβ after injury</td>
<td>2–24 h</td>
<td>Interstitial fluid</td>
<td>[112]</td>
</tr>
<tr>
<td>Mouse (PDAPP) crossed with apoE3 and apoE4</td>
<td>Controlled cortical impact</td>
<td>56% apoE4/PDAPP; increase Aβ deposition and amyloid plaques; 20% apoE3/PDAPP; increase Aβ deposition and amyloid plaques</td>
<td>3 months</td>
<td>Hippocampus</td>
<td>[100]</td>
</tr>
<tr>
<td>Mouse (ApoE3/ ApoE4), or ApoE null mice</td>
<td>Closed head injury</td>
<td>ApoE4 Die or poorer outcomes than apoE3</td>
<td>11 days</td>
<td>Cortex</td>
<td>[113]</td>
</tr>
<tr>
<td>Rat (Sprague Dawley)</td>
<td>Weight drop (open skull)</td>
<td>APP accumulation in damaged axons; No accumulating Aβ observed intracellularly or in plaques</td>
<td>1, 3 and 21 days</td>
<td>Cortex and thalamus</td>
<td>[94]</td>
</tr>
<tr>
<td></td>
<td>Lateral fluid percussion</td>
<td>APP accumulation in damaged axons; No accumulating Aβ observed intracellularly or in plaques</td>
<td>1 h, 2 h, 48 h, 1 week, or 2 weeks</td>
<td>Cortex, striatum, cingulum, and hippocampus</td>
<td>[95]</td>
</tr>
<tr>
<td></td>
<td>Lateral fluid percussion</td>
<td>Reduction of Aβ accumulated in damaged axons according with severity of injury</td>
<td>2 days–1 year</td>
<td>White matter, cortex and thalamus</td>
<td>[114]</td>
</tr>
<tr>
<td></td>
<td>Lateral fluid percussion</td>
<td>Increase pTau</td>
<td>6 months</td>
<td>White matter, cortex</td>
<td>[115]</td>
</tr>
<tr>
<td></td>
<td>Weight drop (open skull)</td>
<td>APP and Aβ identified in damaged axons; No Aβ plaques observed</td>
<td>6 h–10 days</td>
<td>White matter</td>
<td>[44]</td>
</tr>
<tr>
<td></td>
<td>Controlled cortical impact</td>
<td>Increase cleaved Tau</td>
<td>6–168 h</td>
<td>Cortex</td>
<td>[116]</td>
</tr>
<tr>
<td>Swine</td>
<td>Rotational acceleration (model of DAI)</td>
<td>APP and Aβ accumulation; Diffuse Aβ plaques; Increase total Tau</td>
<td>3-10 days</td>
<td>White matter and cortex</td>
<td>[117]</td>
</tr>
<tr>
<td></td>
<td>Rotational acceleration (model of DAI)</td>
<td>Aβ, APP, BACE and presenilin-1 accumulation in damaged axons; Diffuse Aβ plaques</td>
<td>3h, 3 days, 6 months</td>
<td>Subcortical white matter</td>
<td>[65]</td>
</tr>
</tbody>
</table>

Table 2. Animal studies on TBI and associated AD pathology.
3. Neuropathology of TBI: related proteins

TBI regulates the expression patterns of several proteins commonly associated with neurodegenerative diseases, such as α-synuclein, amyloid precursor protein, Aβ, TDP-43, and tau [37–40] (Figure 1). Besides, the ApoE4 gene and their cleaved products are implicated in neurodegenerative disorders, axonal pathology, and apoptosis following TBI [41, 42]. TBI also induces caspase-3, which is involved in APP processing, contributing to AD [43, 44]. This increase in APP expression and neuroinflammatory response following injury may contribute to a cycle of Aβ deposition and microglial activation that ultimately result in chronic neuropathology [45, 46]. In this section, I will summarize the principal proteins involved in TBI and AD and their associated factors in the neurodegenerative process.

3.1 Amyloid precursor protein (APP)

APP and its proteolytic derivatives are important mediators of neuronal synaptogenesis and synapse maintenance [47]. APP functions in the axonal transport of vesicles and presenilin (PS) regulate intracellular protein trafficking, highlighting the role of APP as a synaptic vesicle protein [47]. TBI leads to overexpression...
of APP within neuronal cell bodies and APP accumulation within injured axons [48] (Figure 2C). Postmortem studies on human brain tissue samples from patients who have sustained mild TBI, but died due to other causes, have shown that APP accumulation occurs very rapidly (within a few hours) after brain [49]. Once mature, APP can be processed by two mutually exclusive complex pathways, either the non-amyloidogenic or the amyloidogenic pathway [50]. The non-amyloidogenic pathway accounts for the majority of APP processing and results in the secreted APP (sAPPα) via α-secretase cleavage [51]. The β- and γ-secretase pathway is responsible for producing secreted APPβ (sAPPβ) and the toxic Aβ, which is found within amyloid plaques in AD [52]. Both axonal APP accumulation and long-term accumulation of Aβ has been reported in injured axons following TBI [53]. This large reservoir of APP in axons might be aberrantly cleaved to form Aβ [49]. Evidence for the role of caspase-3 in APP cleavage and Aβ production has come from recent studies examining the effects of caspase inhibition following trauma [43]. APP undergoes sequential proteolysis to produce plaque-forming Aβ peptides.

3.2 Amyloid β formation and amyloid plaques

3.2.1 Protein amyloid-β

Amyloid is a highly-ordered filamentous protein aggregate generally regarded as a misfolding event in which proteins that are soluble accumulate into fibrous structures [54]. However, determinants of amyloid formation and toxicity are largely unknown.

Edema, inflammatory response, vasculature changes, and deposition of Aβ have all been found to be localized pathological changes after TBI [55]. As such, an understanding of the mechanism promoting AD risk is important. Although TBI is typically believed to be a static pathological insult from a single event, new clinical unrecognized clinical symptoms can arise many years after the initial injury. In human studies, TBI has been shown to result in amyloid deposits reminiscent of AD pathology. Aβ immunoreactivity and protein expression increase for as long as a year after injury, indicating that Aβ aggregation and plaques formation may continue long after APP gene expression returns to normal. Plaques found in TBI patients are strikingly similar to those observed in the early stages of AD [13, 14]. However, TBI-associated plaques can appear rapidly (within hours) after injury, whereas plaques in AD develop slowly and are found predominantly in the elderly [13].

Monomeric forms of Aβ can aggregate to form oligomers, protofibrils; these fibrils deposit as amyloid plaque (Figure 1), unaggregated oligomeric forms of Aβ may contribute to toxicity after TBI [56]. Aβ causes apoptotic cell death of neuronal cells in culture by the induction of caspases, known instigators of apoptotic cell death [57]. Accumulation of Aβ deposits, hippocampal damage, and chronic inflammation were found mainly in subcortical regions [18]. Early microglial accumulation in AD delays disease progression by promoting clearance of neurotoxic Aβ peptides before the formation of senile plaques. However, as AD mice age, microglia become dysfunctional, producing proinflammatory cytokines in response to Aβ aggregation downregulate genes involved in Aβ clearance [58].

3.2.2 Mechanisms of post-traumatic amyloid-β formation

The intracellular accumulation of Aβ, extracellular deposition of soluble Aβ plaques, and aggregation of tau protein have all been observed in patients, sometimes within hours after severe brain injury [59, 60]. Aβ accumulation and amyloid
Figure 2. Representative immunohistochemical images showing neurodegenerative markers in a mouse model of Alzheimer’s disease after brain injury. (A) Aβ plaques detected using Aβ42 antibody in the cortex of AD model mice (3xTg-AD, 9 months old mice) (inset in A, high magnification in a). (B) Aβ plaques detected using Thioflavin-S staining in the cortex of old 3xTg-AD (B, high magnification in b). (C) Representative broken axons stained with APP showing axonal bulbs found acutely following TBI in wild-type mice. (D–F) Aβ42 diffuse plaques were identifying using an antibody specific for Aβ42 and were not detected by Thioflavin-S staining, in the CA1 hippocampal region (D), in the corpus callosum (E), and in the cortex (F) of wild-type mice. (G–H) Hippocampal neurons were stained using an antibody for phosphorylated tau in the CA1 hippocampus (G, high magnification in g) and cortical pyramidal layer (H, high magnification in h) after TBI in old 3xTg-AD mice. Scale bars: 200 μm (A), 50 μm (B–H), and 20 μm (a, b, f, g, and h).
Neuropathology of Traumatic Brain Injury and Its Role in the Development of Alzheimer’s Disease

DOI: http://dx.doi.org/10.5772/intechopen.81945

deposition precede the cognitive decline in Alzheimer’s disease, with the pathology arriving later, and is associated with non-Alzheimer’s disease dementia. Deposition of amyloid plaques from Aβ peptide in Alzheimer’s disease or acute phase of TBI have previously been reported to involve either mononuclear phagocytes, endocytic uptake, or proteolytic processing of the APP during fibril formation [61, 62]. Levels of Aβ were found to be high days after TBI and then declined towards control levels in the subsequent 2 weeks. It has been suggested that a long-term process of Aβ metabolism is initiated by TBI, which can be cleaved to form Aβ. Both species of Aβ, Aβ40, and Aβ42, are increased in the first week after injury in the CSF of TBI patients; other studies have shown comparatively lower Aβ40 levels compared to high levels of Aβ42 [63]. Intracellular Aβ accumulation of non-plaque species of Aβ is more common than plaque deposition after TBI. Aβ is produced by sequential cleavage of the amyloid precursor protein APP via two enzymes, β- and γ-secretase. Depending on the cleavage point of γ-secretase, Aβ peptides of different amino acid length are produced. The two most closely linked to AD are Aβ40 and Aβ42 [64]. The accumulation of Aβ peptides is thought to be a major initiator event in AD pathogenesis (Figure 1). TBI leading to impaired axonal transport induces a long-term pathological co-accumulation of APP with β-site APP-cleavage enzyme 1 (BACE1), presenilin 1 and activated caspases, thus providing a possible mechanism for APP cleavage and production of Aβ within axons following TBI [65]. The release of Aβ (especially Aβ42) into tissue and plaque formation around damaged axons occurs after APP accumulation and Aβ production in damaged axons. Both presenilin-1 (PS1) and BACE were found in swollen axons in the swine model and in humans (Table 2). Targeting the APP secretase enzymes can prevent the increase in Aβ after TBI [19], specifically, Aβ42 was found to accumulate in the axonal bulbs of injured brains [22]. BACE1 and PS1 were increased in the damaged axons of TBI patients, and our previous studies have also shown that BACE1 and PS1 are considered the promising targets for the treatment of TBI [19].

Plaques have also been observed in pericontusional tissue surgically excised from survivors of TBI. Nevertheless, the key pathological similarity between TBI with AD is the observation that Aβ plaques are found in up to 30% of patients who die of acute TBI [14]. While TBI-associated plaques largely appear in the gray matter, they have also been identified in white matter. Amyloid plaques consist primarily of aggregated Aβ peptides, which are surrounded by dystrophic neurites, microglia, and reactive astrocytes [66, 67].

3.3 Tau protein and neurofibrillary tangles

The tau protein is associated with microtubules and plays a role in the outgrowth of neuronal processes and the development of neuronal polarity [68]. Misfolded and aggregated tau causes a gain of toxic function by hindering normal and axonal processes; axonal neurodegeneration due to the loss of tau is caused by a decrease in tau microtubule binding capabilities [69, 70]. Tau oligomerization is known as a critical mechanism in the development of NFTs, consisting of hyperphosphorylated tau proteins with pathological function [71]. AD is also characterized by intracellular hyperphosphorylated tau that constitutes the NFTs and senile plaques and is one of the most common tauopathies [72]. Furthermore, toxic tau proteins increase within hours after clinical brain injury [22], and their release and spreading effect may also contribute to the development of tauopathy following TBI [73]. It was described that the spatial pattern of the tau-immunoreactive pathology observed in chronic traumatic encephalopathy (CTE) is typical of the tauopathies [74]. The tau from both TBI and AD brains is phosphorylated at the same amino acids, resulting in the proteolytic cleavage of six isoforms known as
cleaved tau (c-tau), including the AT8 epitope [75]. Hyperphosphorylated Tau has been shown to increase between 1 and 7 days after moderate TBI in triple transgenic AD mice [76] and at 3 weeks after repetitive mild TBI in the human Tau (hTau) tauopathy mouse model [77] (Table 2). Experimental studies in animal models suggest that intra-axonal tau accumulation and tau phosphorylation may be in fact the consequences of repeated brain trauma or dementia pugilistica/CTE [78]. Today, CTE is used to define the neurological sequelae and neuropathological changes that occur as a result of repeat concussive or subconcussive blows to the head. Besides, the pathology of CTE is also characterized as a tauopathy, a class of neurodegenerative disease caused by the pathological aggregation of tau protein [78]. In CTE, NFTs also consist of hyperphosphorylated and ubiquitinated tau [79, 80]. Tau degradation in boxers with CTE are structurally and chemically similar to those seen in AD and frontotemporal lobar degeneration (FTLD) [80]. Treatment with γ-secretase inhibitors diminishes amyloid pathology but does not affect TBI-induced tangle formation, suggesting that TBI-induced tau pathology is not a downstream event of Aβ and plaque formation [81].

3.4 TDP-43 pathology

TAR DNA-binding protein (TDP-43) protein has been identified as a regulator of gene expression and exon splicing with DNA and RNA binding capabilities. Hence, though TDP-43 is synthesized in the cytoplasm and resides in the nucleus of neurons and glia, under pathological conditions TDP-43 is accumulated in the cytoplasm in the form of ubiquitinated and hyperphosphorylated inclusions [82] (Figure 1). Pathological TDP-43 has been identified as the main disease-associated protein in ALS and FTLD. It has also been recognized as a secondary feature in many other neurodegenerative diseases, including Huntington disease, AD and PD [83]. Axonal damage results in an upregulation of TDP-43 expression, together with a redistribution of TDP-43 from the nuclear compartment to the cytoplasm [33, 84]. TBI induces TDP-43 abnormalities that can contribute to the neurological consequences of TBI, such as worse cell death, and cognitive deficits [85]. TDP-43 proteinopathy is also part of the acute or delayed pathological sequelae of repetitive mild, concussive TBI or CTE pathogenesis [86, 87]. The TDP-43 proteinopathy associated with CTE is similar to that found in FTLD with TDP-43 inclusions [87]. Intraneuronal accumulation of non-phosphorylated TDP-43 after a single TBI has also been reported [88]. Contrarily, related studies failed to demonstrate an association between single TBI and TDP-43 proteinopathy, only with repetitive TBI, indicating that just many insults reinforcing acute upregulation are sufficient to cause TDP-43 aggregation. Importantly, aggregates of phospho-TDP-43 were not increased long-term following TBI [88]. To the best of our knowledge, a clear functional role of altered TDP-43 expression levels after TBI has not been demonstrated, though this might disrupt signaling pathways involved in neuronal dysfunction, as some authors have suggested [89].

4. AD pathology in animal models of brain trauma

Several experimental animal models of TBI have been utilized in the attempt to replicate amyloid and tau pathologies, as well as other proteinopathies associated to AD. Some of these have been summarized in Table 2. Animal models of TBI show elevated Aβ levels, Aβ production, and Aβ deposition, specific to the brain region and anatomy and varying with the type of injury. Observed in mice
that overexpress normal human APP, there is an increase in tissue concentrations of Aβ after injury, associated with an increase in hippocampal neuronal death and memory impairment [43]. However, TBI alone does not seem to induce acute plaque formation systematically. Controlled cerebral impact (CCI) injury in an APP transgenic mouse model (PDAPP) has been shown to result in a spike in Aβ40 and Aβ42, peaking at 2 h post-injury and returning to baseline by 6 h [90]. Studies in PDAPP mice over greater intervals have shown that CCI can decrease the deposition of Aβ in the ipsilateral cortex and hippocampus, up to 4–8 months after injury, compared to the uninjured side of the brain [91]. Additionally, CCI injuries, using in a different APP transgenic mouse model (Tg2576), have been shown cause elevated soluble and insoluble cortical Aβ40 and Aβ42 levels as well as amyloid plaque deposition [92]. Finally, studies in APPNLh/NLh mice, a gene-targeted mouse model that expresses normal levels of human APP, yielded elevated Aβ40 levels via inhibition of caspase-3 activity, only for the first 24 h after CCI, while Aβ42 levels remain elevated through 14 days [43]. Repetitive TBI is known to cause cumulative damage. After mild TBI in mice, during two consecutive days, studies have reported delayed recovery from fine motor coordination deficits as well as evidence of enhanced blood-brain barrier breakdown accompanied by axonal injury [21]. A recent study in an animal model using a triple-transgenic mouse model of Alzheimer’s disease (3xTg-AD), the effect of repetitive mild TBI caused an increase of tau hyperphosphorylation and activation of asparaginyl endopeptidase (AEP), a cysteine proteinase which is known to be involved in tau phosphorylation [93].

In contrast, repetitive TBI in a Tg2576 APP-transgenic mice model did result in greater Aβ deposition as well as an increase in the production of both soluble and insoluble cortical Aβ40 and Aβ42, which may be a result of the higher levels of oxidative stress after repetitive TBI [92]. However, TBI does not lead to early amyloid plaque formation in transgenic mice, and at later times there is a reduction in amyloid plaques in ipsilateral injury regions [90, 91]. Also, Aβ accumulation was identified in damaged axons shortly after brain injury, albeit still in the absence of Aβ plaques [94, 95]. However, the lack of evidence of Aβ deposition in non-transgenic animals was attributed, in part, to differences in the Aβ peptides found in different species. Experimental results of moderate and severe TBI studies in transgenic models of AD are also contrasted with that seen in human TBI (Table 1). First, rapid Aβ deposition has not been demonstrated in any of the described transgenic models, unlike human studies [34, 36, 96, 97]. Second, increased severity of the injury does not result in increased Aβ deposition; instead, it seems to correlate with reduced Aβ deposition or possibly resolution of previously established plaques, as reported by [98]. In summary, all the animal models mentioned above provide important information regarding the potentially detrimental consequences of elevated Aβ levels following TBI. However, post-traumatic Aβ deposition has not been observed in the majority of non-transgenic animal studies; most failed to identify plaque pathology that is commonly observed following human TBI. To better understand the effects of repeat trauma on the brain, an animal model that can model the disease after repetitive trauma is required. Unfortunately, such an experimental model does not yet exist and will be challenging to generate.

5. Apolipoprotein E4 allele and TBI increase the risk of developing AD

The epidemiology of both AD and TBI are dominated by a single genetic risk factor, the APOE genotype. In humans, there are three distinct isoforms of
the protein: apoE2, apoE3, and apoE4, distinguished by three alleles [99]. The apoE ε4 allele confers strong susceptibility for AD and is also the factor for the development of amyloid plaques after TBI. Furthermore, the apoE ε4 allele has been associated with increased Aβ in the cerebral cortex and unfavorable outcome after TBI [100]. ApoE4 individuals were over 10 times more likely to develop AD after severe TBI than those who did not posses the allele [101], and the presence of an apoE4 allele is linked to poor recovery from extended coma. Professional boxers containing the apoE ε4 allele were at increased risk of CTE compared to boxers without the apoE ε4 allele [102]. This finding suggests that genetic factors may strongly influence the risk of CTE after brain injury. However, the possibility remains that certain boxers may be innately ‘resistant’ to developing AD or dementia following CTE; definitely, not all boxers go on to develop AD, despite repetitive injury and having the higher risk genotype. Consistent with a role of ApoE protein in amyloid deposition in humans, apoE4 also increases amyloid plaque formation in mice. Aβ deposition is also significantly increased following head trauma in PDAPP (platelet-derived growth factor promoter expressing amyloid precursor protein) mice carrying the human apoE ε4 allele versus those carrying apoE ε3 or no apoE (Table 2) [103]. Finally, transgenic APOE ε4 mice, which also overexpress APP, show accelerated deposition of Aβ following injury, suggesting apoE ε4 may reduce the clearance of Aβ, thereby favoring its deposition [100] (Table 2). Some recent reports are controversial clinical and preclinical studies about the link between poor outcome after severe and mild TBI and the APOE4 gene [11, 16, 30, 104, 105].

6. Similarities and differences in the neuropathology of TBI and AD

The similarities and differences in the neuropathology associated to TBI and AD are complex. Aβ formation and aggregation, tau phosphorylation, including other proteins found in the brain and CSF following TBI, share a lot of similarities with AD, but also several evident differences. Principally, the localization and distribution of proteins in TBI patients are fundamentally distinct from the characteristic pattern commonly observed in AD [13]. However, one strong similarity between TBI and AD is in the Aβ plaque formation; both are primarily composed of Aβ 41–42, furthermore, CSF levels of Aβ are increased similarly for both [106]. However, in AD there are numerous, compact, core Aβ aggregates in addition to neurofibrillary tangles and neuropil threads, this in contrast to TBI where there appears to be a higher prevalence of diffuse Aβ plaques [34, 36]. Notably, Aβ plaques in TBI are typically described as diffuse and do not display the histochemical or morphological features of the senile plaques that are characteristic of AD [35]. Aβ toxicity only emerges when levels exceed a certain threshold, and unaggregated oligomeric forms of Aβ may contribute to toxicity. As such, rapid aggregation of Aβ into plaques may be a protective event following TBI [73]. In CTE, the tau inclusions are morphologically most similar to those found in AD, with pyramidal neurons maintaining their shape, and tangles consisting of hyperphosphorylated and ubiquitinated tau [84]. This phospho-tau staining was also observed in axons and clusters of neuronal cell bodies in the cerebral cortex and hippocampus (Figure 2G and H). Such studies have also noted the existence of tau-positive reactive astrocytes in AD, a pathology that is not usually associated with AD. Finally, the tau immunoreactive profile of CTE is characteristically very patchy and irregular, with preferential deposition in the superficial necortical layers, while tangles in AD are found in deep and superficial layers [33]. In summary, while there are certain important differences between mild, moderate, and severe TBI and dementia or AD, given the significant overlap
7. Conclusions

The association between trauma and the onset of neurodegenerative diseases, such as AD, is extremely convoluted, further complicated by the absence of appropriate animal models able to reproduce human pathologies. Elucidation of this nature of this link remains in its infancy, requiring extensive further research to chip away at the underlying relationship. Moreover, quantification of the relative contributions of various risk factors for developing these pathologies, such as cellular and molecular mechanisms, frequency and severity of the injury, age, sex, and potential genetic predisposition, remain mostly imprecise. Although we do not know how TBI fundamentally impacts the long-term outcome and affects the risk of dementia, it remains clear that amyloid pathways play an important role in secondary injury and acute cell death after trauma. Continued efforts to investigate why TBI, and repeat concussions, may lead to AD and other associated dementias are required. Further understanding of the molecular mechanism underlying these events is required, achievable via better designed animal models able to more closely and accurately mimic the observed behavioral and pathological changes. Only then will we be well equipped to precisely evaluate novel therapeutic agents that may intervene in the disease process. Future research will be required to uncover the mechanisms through which TBI increases the risk of AD, opening the door to designer treatment strategies for the full scope of post-traumatic injuries.

Acknowledgements

This work was supported by R21NS106640 (SV) and R03NS09503 (SV) from the National Institute for Neurological Disorders and Stroke (NINDS).

Conflict of interest

There are no conflicts of interest to disclose.
Author details

Sonia Villapol

1 Center for Neuroregeneration and Department of Neurosurgery, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX, USA

2 Department of Neuroscience in Neurological Surgery, Weill Cornell Medical College, NY, USA

*Address all correspondence to: svillapol@houstonmethodist.org
References


Amyloid Diseases


Cowan CM, Quraishe S, Mudher A. What is the pathological significance of tau oligomers?
encephalopathies: Studies of a retired NFL player and of a man with FTD and a severe head injury. Translational Psychiatry. 2014;4:e441


Neuropathology of Traumatic Brain Injury and Its Role in the Development of Alzheimer's Disease

DOI: http://dx.doi.org/10.5772/intechopen.81945


[105] Han SD, Drake AI, Cessante LM, Jak AJ, Houston WS, Delis DC, et al. Apolipoprotein E and traumatic brain...


